Lexaria advances oral dosing study for next-gen GLP-1 drugs
Lexaria Bioscience Corp. has completed dosing in its 2026 Animal Study #2, evaluating retatrutide and amycretin with its DehydraTECH technology. The study investigates 18 arms to assess pharmacokinetic performance and tolerability, aiming to reduce side effects like nausea. This self-sponsored research seeks to expand DehydraTECH's applicability to triple-agonist weight-loss peptides.
*this image is generated using AI for illustrative purposes only.
Lexaria Bioscience Corp. has completed dosing in its 2026 Animal Study #2 (GLP-1-A26-2), evaluating formulation enhancements for two next-generation glucagon-like peptide-1 (GLP-1) drugs using its proprietary DehydraTECH technology. The study aims to explore potential improvements in drug delivery performance and stake new intellectual property claims. Dosing for the study was finalized on June 9, 2026, in Kelowna, BC.
The investigation focuses on retatrutide, owned by Eli Lilly and Company, and amycretin, owned by Novo Nordisk. Retatrutide is a triple hormone receptor agonist targeting GLP-1, glucagon, and GIP, currently administered via weekly injections. Lexaria's study examines oral dosing through tablets and capsules, comparing absorption primarily through the stomach or intestine.
Study Objectives and Methodology
The study comprises 18 different arms to evaluate novel DehydraTECH compositions. Blood samples are collected over a 24-hour post-dosing period to quantify pharmacokinetic (PK) performance. Primary goals include assessing compatibility with retatrutide and amycretin, centered on PK performance and tolerability.
| Study Component | Details |
|---|---|
| Study Name | 2026 Animal Study #2 (GLP-1-A26-2) |
| Drugs Evaluated | Retatrutide, Amycretin |
| Formulations | Tablets, Capsules |
| Study Arms | 18 |
| Sampling Period | 24 hours post-dosing |
Technology and Potential Benefits
DehydraTECH is Lexaria's patented drug delivery platform designed to improve oral drug bio-absorption and reduce side effects. The study evaluates alternative formulations to salcaprozate sodium (SNAC) technology used in Novo Nordisk's Rybelsus and Wegovy. Compositions include sodium caprate, a delivery enabling compound shown to influence gastrointestinal absorption.
Common side effects of GLP-1 drugs include nausea, diarrhea, and vomiting. Lexaria aims to demonstrate that DehydraTECH processing may lower the severity and frequency of these side effects while maintaining or improving efficacy.
Strategic Implications
Richard Christopher, CEO of Lexaria Bioscience, described the study as a watershed moment for the company's GLP-1 investigations. Success would expand DehydraTECH's applicability to triple-agonist weight-loss peptides in late-stage development, potentially dominating future markets. The study is fully self-sponsored and funded from existing corporate resources.
What are the potential licensing or partnership opportunities with Eli Lilly and Novo Nordisk if the study results prove successful?
How might the introduction of an effective oral formulation impact the market share of current injectable GLP-1 therapies?
What are the next regulatory milestones Lexaria must achieve to advance these formulations into human clinical trials?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
